Literature DB >> 712119

Prediction of efficacy of antimicrobial agents in treatment of infections due to Chlamydia trachomatis.

W R Bowie, C K Lee, E R Alexander.   

Abstract

Although Chlamydia trachomatis is readily eradicated by systemic therapy in patients with acute urethritis, systemic therapy is less satisfactory in treatment of chronic trachoma. The activities of antimicrobial agents against C. trachomatis in cell cultures when the antimicrobial agents are added 1 hr after the C. trachomatis (minimal inhibitory concentration [MIC]) predicts efficacy of the drugs in the treatment of urethritis but does not necessarily predict efficacy in the treatment of chronic ocular trachoma. Concentrations of antimicrobial agents required to eradicate C. trachomatis when the agents were added 48 hr after inoculation of the cell cultures with C. trachomatis exceeded the MIC by several logarithms, and minocycline, doxycycline, and rifampin were markedly more active than tetracycline, erythromycin, or several other antimicrobial agents. Of the three most active antimicrobial agents, only doxycycline has been used systemically to treat ocular infections due to C. trachomatis, and it has been reported to be the most effective antimicrobial agent that has been utilized. In vitro testing of obligate intracellular pathogens such as C. trachomatis presents unique problems. Utilization of several methods of testing may help to identify antimicrobial agents with improved clinical efficacy, particularly in the treatment of ocular trachoma.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 712119     DOI: 10.1093/infdis/138.5.655

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  33 in total

1.  Non-gonococcal urethritis: a comparison of therapy with minicycline, tetracycline and erthromycin.

Authors:  B Romanowski; M Grace
Journal:  Can Fam Physician       Date:  1984-08       Impact factor: 3.275

2.  Genital Chlamydia trachomatis: detection, treatment and patient education.

Authors:  K H Jaczek
Journal:  Can Fam Physician       Date:  1985-10       Impact factor: 3.275

3.  In vitro activity of difloxacin hydrochloride (A-56619), A-56620, and cefixime (CL 284,635; FK 027) against selected genital pathogens.

Authors:  W R Bowie; C E Shaw; D G Chan; J Boyd; W A Black
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

4.  In vitro studies of Chlamydia trachomatis susceptibility and resistance to rifampin and rifabutin.

Authors:  J D Treharne; P J Yearsley; R C Ballard
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

5.  In vitro activities of lomefloxacin, tetracycline, penicillin, spectinomycin, and ceftriaxone against Neisseria gonorrhoeae and Chlamydia trachomatis.

Authors:  H Talbot; B Romanowski
Journal:  Antimicrob Agents Chemother       Date:  1989-12       Impact factor: 5.191

Review 6.  Gynecological chlamydial infections.

Authors:  L Weström
Journal:  Infection       Date:  1982       Impact factor: 3.553

7.  Comparison of the in vitro activities of ofloxacin and tetracycline against Chlamydia trachomatis as assessed by indirect immunofluorescence.

Authors:  J M Bailey; C Heppleston; S J Richmond
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

8.  Dose-ranging study of fleroxacin for treatment of uncomplicated Chlamydia trachomatis genital infections.

Authors:  W R Bowie; V Willetts; D W Megran
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

9.  Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro.

Authors:  U Dreses-Werringloer; I Padubrin; H Zeidler; L Köhler
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

10.  Lack of in vitro activity of cefoxitin, cefamandole, cefuroxime, and piperacillin against Chlamydia trachomatis.

Authors:  W R Bowie
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.